1. Introduction

Biotechnology Reparative Justice Theory is a developing interdisciplinary legal and ethical framework concerned with repairing harm caused by the development, testing, commercialization, distribution, or misuse of biotechnology.

It asks a fundamental question: When biotechnology generates scientific progress or commercial profit at the expense of individuals, vulnerable communities, research participants, or the environment, what obligations do the responsible parties have to repair the resulting harm?

The theory draws on established principles of tort law, constitutional law, bioethics, human rights, environmental law, intellectual property, and distributive justice. It is not, however, a universally recognized standalone legal doctrine with a single settled definition. Rather, it is a useful analytical framework for interpreting existing legal rules and proposing reforms.

For example, suppose a biotechnology company collects genetic samples from an indigenous community, develops a commercially successful medicine, and excludes the community from meaningful participation or benefits. Reparative justice would examine whether the collection was lawful, whether consent was valid, whether cultural or privacy rights were violated, and what remedies could address the harm.

Those remedies might include compensation, restoration of rights, public acknowledgment, access to resulting treatments, community benefit-sharing, or reforms to prevent similar misconduct.

2. Meaning and definition

The theory combines three important concepts.

Biotechnology: The use of biological systems, organisms, cells, genes, or biological processes to develop products and technologies, including gene therapies, vaccines, genetic tests, genetically modified crops, and engineered biological materials.

Reparative justice: The obligation to address wrongful harm through remedies that go beyond merely declaring that a violation occurred.

Theory: A structured set of principles used to evaluate responsibility, determine appropriate remedies, and prevent the recurrence of injustice.

A working definition is:

Biotechnology Reparative Justice Theory is a framework for identifying and remedying injuries arising from biotechnology-related activities, with particular attention to accountability, informed consent, equitable distribution of benefits, recognition of affected persons, and institutional reform.

The central idea is that scientific innovation does not automatically excuse the violation of human rights, and financial compensation alone may not adequately repair every biotechnology-related injury.

3. Objectives of the theory

1. Recognition of injury

Establish that unauthorized use of biological material, discriminatory genetic profiling, unsafe experimentation, or environmental damage may create legally and ethically significant harm.

2. Fair compensation

Provide appropriate compensation for bodily injury, financial loss, privacy violations, unlawful exploitation, or other legally recognized injuries.

3. Equitable benefit-sharing

Examine whether people and communities whose contributions enabled a biotechnology product should receive legally required or contractually agreed benefits.

4. Prevention and accountability

Improve consent procedures, safety monitoring, regulatory supervision, disclosure, and corporate governance to reduce repeated violations.

4. Core principles of Biotechnology Reparative Justice Theory

A. Corrective justice

Corrective justice focuses on the relationship between the person responsible for a wrongful injury and the person who suffers it. Where the law establishes liability, the responsible party may be required to restore the injured person, as far as possible, to the position they would have occupied without the wrong.

In biotechnology, this may involve compensation for an injury caused by negligent clinical trials, a remedy for fraudulent research practices, or damages for a proven breach of informed consent.

The remedy depends on the applicable cause of action and the evidence. A harmful outcome alone does not necessarily establish legal liability.

B. Restorative justice

Restorative justice seeks to address the broader consequences of wrongdoing, including the needs of affected persons and communities.

Possible measures include:

A formal acknowledgment of misconduct.

Correction of inaccurate public statements or research records.

Return, destruction, or restricted use of biological samples where legally and practically appropriate.

Community consultation and negotiated remediation.

Institutional reforms and continuing oversight.

This approach is especially relevant where the harm involves dignity, trust, cultural identity, or the integrity of scientific research.

C. Distributive justice

Distributive justice examines how the benefits and burdens of biotechnology are allocated.

A biotechnology innovation may benefit investors, patent holders, healthcare institutions, and patients, while its risks are concentrated among research participants or disadvantaged communities.

The theory therefore asks whether the allocation of risks, profits, and access to treatment is fair.

However, distributive fairness does not automatically create a legal right to royalties or ownership. Such entitlements depend on applicable legislation, contracts, intellectual-property rules, and other recognized legal grounds.

D. Procedural justice

Procedural justice concerns fairness in the processes through which biotechnology decisions are made.

Relevant safeguards include informed consent, independent ethics review, transparent risk disclosure, accessible complaint mechanisms, fair hearings, and meaningful opportunities to challenge regulatory decisions.

A reparative system is incomplete if affected persons cannot realistically establish what happened or obtain an effective remedy.

E. Intergenerational and environmental justice

Biotechnology can create risks that extend beyond the immediate participants, including ecological disruption, loss of biodiversity, and potentially persistent environmental effects.

A reparative approach may therefore consider environmental restoration, long-term monitoring, containment measures, and the interests of future generations.

The precise legal duties depend on the type of technology, the evidence of risk or damage, and the governing environmental and biosafety legislation.

5. Important case laws on Biotechnology Reparative Justice

The following judgments do not establish a single doctrine called “Biotechnology Reparative Justice Theory.” Instead, they provide legal principles that can be used to develop and apply the framework.

Case 1: Moore v. Regents of the University of California (1990)

Supreme Court of California · 51 Cal. 3d 120 · 793 P.2d 479

Facts: John Moore received treatment for leukemia. His physicians used cells taken from him to develop a commercially valuable cell line without adequately disclosing their research and commercial interests. The cell line was patented, and commercial arrangements were made involving the resulting technology.

Legal issues:

Could Moore claim ownership-based damages for the commercial use of his excised cells?

Did the physicians breach duties of disclosure and informed consent?

What remedies were available when medical trust and autonomy were compromised?

Judgment: The California Supreme Court rejected Moore's conversion claim based on ownership of the excised cells and the patented cell line. However, it allowed claims based on the physicians' alleged failure to disclose material personal interests, including potential conflicts of interest and breach of fiduciary duty, to proceed.

Justia Law+1

Relevance to reparative justice:

The case illustrates the distinction between owning biological material and having legally protected rights to informed consent and honest disclosure.

A reparative approach could support remedies where misconduct is established, such as damages for legally actionable breaches, improved consent procedures, disclosure of commercial interests, and institutional accountability.

Critical limitation: The decision does not establish a general right for tissue donors to receive royalties from every product developed using their biological material.

Case 2: Samira Kohli v. Dr. Prabha Manchanda (2008)

Supreme Court of India · (2008) 2 SCC 1 · AIR 2008 SC 1385

Facts: Samira Kohli consented to a diagnostic procedure. While she was under anaesthesia, her doctor performed additional therapeutic surgery without obtaining the required consent for that procedure.

Legal issue: Can consent for one medical procedure authorize a substantially different procedure simply because the doctor believes the additional procedure would benefit the patient?

Judgment: The Supreme Court held that consent must be real and valid: it must be voluntary, given by a competent person, and based on adequate information. Consent for a diagnostic procedure does not ordinarily authorize a different therapeutic procedure. A narrowly defined exception applies where an additional procedure is necessary in an emergency and delay would unreasonably endanger life or health.

Indian Kanoon+1

Relevance to biotechnology reparative justice:

This judgment provides a strong foundation for analyzing consent in biomedical research, genetic testing, tissue collection, and experimental interventions.

For example, consent to provide a blood sample for diagnosis should not automatically be treated as consent to every unrelated research or commercial use. The precise consent requirements depend on the applicable law, research protocol, and circumstances.

Where unauthorized conduct causes a legally recognized injury, appropriate remedies may include compensation, regulatory action, or institutional reform.

Case 3: Association for Molecular Pathology v. Myriad Genetics, Inc. (2013)

Supreme Court of the United States · 569 U.S. 576

Facts: Myriad Genetics identified the locations and sequences of the BRCA1 and BRCA2 genes, which are associated with increased risks of breast and ovarian cancer, and obtained patents relating to them.

Legal issue: Are naturally occurring human DNA sequences patent-eligible merely because a researcher has isolated them?

Judgment: The US Supreme Court held that naturally occurring DNA segments are not patent-eligible merely because they have been isolated. It distinguished naturally occurring DNA from complementary DNA (cDNA), which may be patent-eligible subject to the applicable legal requirements.

LII / Legal Information Institute

Relevance to reparative justice:

The case helps explain why the legal system must distinguish scientific discovery from human-engineered innovation.

From a reparative perspective, patent rules can affect access to genetic testing, competition, research freedom, and the distribution of biotechnology's benefits.

Nevertheless, Myriad was a patent-eligibility decision, not a ruling that compensates research participants or recognizes a general right to share in commercial profits.

Case 4: Diamond v. Chakrabarty (1980)

Supreme Court of the United States · 447 U.S. 303

Facts: Ananda Chakrabarty developed a genetically engineered bacterium capable of breaking down components of crude oil.

Legal issue: Could a human-engineered microorganism qualify as patentable subject matter under US patent law?

Judgment: The Court held that the engineered microorganism was patentable subject matter under the statute then in force because it was a product of human ingenuity rather than simply a naturally occurring organism. This did not mean that every living organism or biotechnology invention was automatically patentable.

Relevance to reparative justice:

The decision highlights the tension between rewarding innovation and ensuring that biotechnology serves legitimate public interests.

A reparative framework may examine whether an invention developed from improperly obtained samples, unlawful research, or violations of benefit-sharing obligations should trigger separate legal remedies. Patentability alone does not determine whether the underlying research was ethically or legally conducted.

Case 5: Canterbury v. Spence (1972)

United States Court of Appeals for the District of Columbia Circuit · 464 F.2d 772

Principle: This decision is a foundational US informed-consent case. It examined the physician's duty to disclose material risks so patients can make informed decisions about medical treatment.

Relevance: Biotechnology frequently involves unfamiliar risks, uncertain outcomes, genetic information, and experimental procedures. Meaningful disclosure is therefore important to prevent injury and to support accountability when consent requirements are violated.

The decision is especially useful as a comparative-law authority, but it should not be treated as binding law in India.

6. International law and reparative justice

A. Nagoya Protocol on Access and Benefit-sharing (2010)

The Nagoya Protocol is particularly relevant when biotechnology research uses genetic resources or associated traditional knowledge obtained from countries and communities that fall within its applicable framework.

Articles 5 and 6 address fair and equitable benefit-sharing and prior informed consent for access to genetic resources, subject to the Protocol's terms and applicable domestic law.

Convention on Biological Diversity+1

Benefits may include:

Upfront payments, royalties, and research funding.

Participation in research and product development.

Technology transfer and training.

Joint ventures and, where agreed, intellectual-property interests.

Support for conservation and local development.

Convention on Biological Diversity+1

Illustration: A research organization uses genetic resources obtained from a provider country to develop a commercially valuable biotechnology product. Where the Protocol and relevant domestic access-and-benefit-sharing rules apply, the organization may need to comply with applicable consent, permit, contractual, and benefit-sharing requirements.

Reparative justice becomes relevant if unlawful access or a breach of agreed obligations causes harm. The remedy must be determined under the applicable legal framework; the Protocol does not create an unrestricted entitlement to compensation for every person whose biological material contributes to research.

B. Convention on Biological Diversity (1992)

The Convention on Biological Diversity provides an international framework for biodiversity conservation, sustainable use, and fair benefit-sharing arising from the utilization of genetic resources.

Its principles are relevant to biotechnology involving genetic resources, biodiversity, and traditional knowledge.

From a reparative perspective, these principles support attention to the communities and countries that supply biological resources and to the ecological consequences of their exploitation.

C. Human rights principles

The rights to dignity, privacy, bodily autonomy, equality, and access to justice can provide a foundation for addressing biotechnology-related misconduct.

Depending on the facts and applicable law, these principles may support claims involving genetic discrimination, unauthorized disclosure of genomic data, coercive experimentation, or unequal treatment in access to biotechnology-derived healthcare.

However, the legal status and enforceability of each right vary across jurisdictions. International human rights principles should be connected to the applicable treaties, constitutional provisions, and domestic legislation rather than assumed to provide an independent remedy in every dispute.

7. Application under Indian law

Biotechnology Reparative Justice Theory can be applied in India through several existing legal frameworks.

These laws operate differently. A constitutional claim, a contract claim, a consumer complaint, and a biodiversity-related proceeding have different requirements for standing, evidence, jurisdiction, and remedies.

Indian case law relevant to the framework

1. Justice K.S. Puttaswamy (Retd.) v. Union of India (2017), (2017) 10 SCC 1

The Supreme Court recognized privacy as a fundamental right under the Constitution.

Application: Genetic and genomic information can reveal intimate personal information. Privacy principles are therefore relevant when examining unlawful collection, disclosure, retention, or use of genetic data. Whether a particular use violates the law depends on its circumstances and the applicable legal protections.

2. Samira Kohli v. Dr. Prabha Manchanda (2008), (2008) 2 SCC 1

As discussed above, the Court emphasized valid consent and the limits of authorization for medical procedures. It is particularly relevant to the autonomy component of biotechnology reparative justice.

3. Indian Council for Enviro-Legal Action v. Union of India (1996), (1996) 3 SCC 212

The Supreme Court addressed environmental pollution and affirmed the polluter-pays principle in the circumstances before it.

Application: Where biotechnology-related activity causes legally established environmental damage, the polluter-pays principle may support recovery of remediation costs and restoration of damaged environments, subject to the applicable law and evidence.

4. Vellore Citizens' Welfare Forum v. Union of India (1996), (1996) 5 SCC 647

The Supreme Court recognized the precautionary principle and polluter-pays principle as important features of Indian environmental law.

Application: These principles are relevant when biotechnology activities create serious environmental risks. They support prevention and remediation, although the specific duties imposed will depend on the applicable statutory and factual context.

Taken together, these authorities support a framework built around autonomy, privacy, equality, environmental accountability, and effective remedies. They do not establish a single, freestanding Indian cause of action named Biotechnology Reparative Justice Theory.

8. Types of reparative remedies

A central proposition of the theory is that the remedy should correspond to the nature of the harm.

1. Compensatory remedies

Damages for proven bodily injury, financial loss, or other legally recognized harm.

2. Restitution and benefit-sharing

Return of property where legally appropriate, repayment of improperly obtained benefits where authorized, or enforcement of valid contractual or statutory benefit-sharing rights.

3. Declaratory and injunctive relief

Court orders recognizing rights or preventing continued unlawful use or disclosure, where the legal requirements for such relief are satisfied.

4. Restorative and collective measures

Environmental remediation, correction of research records, community consultation, and institutional acknowledgment, where appropriate and legally available.

5. Structural reform

Better consent protocols, independent ethics oversight, improved grievance procedures, and compliance monitoring to prevent recurrence.

9. Hypothetical case study

Consider a company that obtains genetic samples from a remote community for a research project. The original consent form authorizes limited medical research, but the company later uses the samples for a commercial genetic product without addressing the relevant consent, regulatory, or benefit-sharing requirements.

The product becomes commercially successful, while members of the community receive no meaningful information about the research or its commercial use.

A reparative-justice analysis would proceed as follows:

Establish the facts: Determine how the samples were collected, what the consent covered, how the samples and data were subsequently used, and which parties were responsible.

Identify the legal violations: Examine consent, privacy, research ethics, contractual obligations, access-and-benefit-sharing rules, and any other applicable legislation.

Determine the injured parties: Distinguish individual injuries from collective or environmental harms and identify who has legal standing to seek a remedy.

Select proportionate remedies: Depending on the established violations, remedies might include compensation, restrictions on further use, enforcement of agreed benefits, corrective disclosures, or institutional reform.

Prevent recurrence: Introduce clearer consent processes, transparent commercial-use terms, independent oversight, and accessible dispute-resolution mechanisms.

The company would not automatically owe every community member a share of all profits. That conclusion would depend on applicable law, contractual arrangements, and the nature of the proven wrong.

10. Criticisms and limitations

The theory offers a valuable framework, but it faces several difficult questions.

Uncertain ownership: Biological material, extracted cells, genetic information, and engineered inventions may have different legal statuses.

Causation: A claimant must often establish a sufficient connection between the defendant's conduct and the claimed injury.

Valuation: Cultural loss, privacy harm, loss of autonomy, and ecological damage can be difficult to quantify.

Innovation concerns: Remedies must address genuine wrongdoing without imposing unjustified liability on researchers who acted lawfully and in good faith.

Collective representation: Communities may disagree about who can negotiate, consent, or receive benefits on their behalf.

Cross-border enforcement: Samples, databases, research institutions, and commercial entities may operate across several jurisdictions.

Unequal bargaining power: A formally voluntary agreement may still raise concerns where a community lacks access to independent advice or meaningful negotiating power.

These difficulties suggest that effective reparative justice requires clear legislation, reliable evidence, independent oversight, and remedies adapted to the particular form of harm.

11. A proposed doctrinal framework

For academic analysis, the theory can be organized into a five-stage test. This is a proposed analytical framework, not an established judicial test.

1

Identification of harm

Has biotechnology caused a legally relevant injury or violated a protected right?

2

Attribution of responsibility

Which researchers, institutions, corporations, or public authorities are legally responsible?

3

Assessment of entitlement

What rights, duties, causal connections, and evidentiary requirements govern the claim?

4

Selection of remedy

Which combination of compensation, restitution, restoration, benefit-sharing, or preventive orders is legally justified?

5

Verification of repair

Has the remedy addressed the established injury, protected affected persons, and reduced the likelihood of recurrence?

12. Conclusion

Biotechnology Reparative Justice Theory provides a way to connect scientific accountability with the legal obligation to remedy wrongful harm. Its significance lies in recognizing that biotechnology disputes are not exclusively questions of patent ownership, scientific progress, or commercial profit. They may also involve bodily autonomy, privacy, human dignity, community rights, environmental protection, and fair access to innovation.

The most useful legal foundations include Moore v. Regents for disclosure and biological-material disputes, Samira Kohli for consent under Indian law, Myriad Genetics and Chakrabarty for patent eligibility, and Indian environmental decisions for remediation and preventive principles. The Nagoya Protocol provides a more direct international framework for certain genetic-resource access and benefit-sharing issues.

The central conclusion is that reparative justice should match the remedy to the wrong: compensation for compensable injury, restoration where possible, fair benefit-sharing where legally required or agreed, and institutional reform where systemic failures contributed to the harm.

For a stronger research paper, the next useful step would be to develop this into a case-law-based doctrinal essay focused specifically on Indian biotechnology law, with statutory provisions, judicial holdings, and critical analysis organized under each principle.